Patents by Inventor Stephen Forman

Stephen Forman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220249560
    Abstract: Chimeric antigen receptors for use in treating lymphoma-associated C-C chemokine receptor type 4 (CCR4) and other cancers expressing CCR4 are described.
    Type: Application
    Filed: May 22, 2020
    Publication date: August 11, 2022
    Inventors: Lihua Elizabeth Budde, Marissa M. Del Real, Stephen Forman
  • Patent number: 9657105
    Abstract: A family of chimeric antigen receptors (CARs) containing a CD123 specific scFv was developed to target different epitopes on CD123. In some embodiments, such a CD123 chimeric antigen receptor (CD123CAR) gene includes an anti-CD123 scFv region fused in frame to a modified IgG4 hinge region comprising an S228P substitution, an L235E substitution, and optionally an N297Q substitution; a costimulatory signaling domain; and a T cell receptor (TCR) zeta chain signaling domain. When expressed in healthy donor T cells (CD4/CD8), the CD123CARs redirect T cell specificity and mediated potent effector activity against CD123+ cell lines as well as primary AML patient samples. Further, T cells obtained from patients with active AML can be modified to express CD123CAR genes and are able to lyse autologous AML blasts in vitro. Finally, a single dose of 5.0×106 CAR123 T cells results in significantly delayed leukemic progression in mice.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 23, 2017
    Assignee: City of Hope
    Inventors: Stephen Forman, Armen Mardiros, Christine E. Brown, Uma Maheswara Rao Jonnalagadda
  • Patent number: 9347102
    Abstract: In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: May 24, 2016
    Assignees: CITY OF HOPE, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Ravi Bhatia, Smita Bhatia, Stephen Forman, Jerald P. Radich, Liang Li, Min Li, Lue Ping Zhao
  • Publication number: 20140271582
    Abstract: A family of chimeric antigen receptors (CARs) containing a CD123 specific scFv was developed to target different epitopes on CD123. In some embodiments, such a CD123 chimeric antigen receptor (CD123CAR) gene includes an anti-CD123 scFv region fused in frame to a modified IgG4 hinge region comprising an S228P substitution, an L235E substitution, and optionally an N297Q substitution; a costimulatory signaling domain; and a T cell receptor (TCR) zeta chain signaling domain. When expressed in healthy donor T cells (CD4/CD8), the CD123CARs redirect T cell specificity and mediated potent effector activity against CD123+ cell lines as well as primary AML patient samples. Further, T cells obtained from patients with active AML can be modified to express CD123CAR genes and are able to lyse autologous AML blasts in vitro. Finally, a single dose of 5.0×106 CAR123 T cells results in significantly delayed leukemic progression in mice.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Inventors: Stephen Forman, Armen Mardiros
  • Publication number: 20130274138
    Abstract: In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 17, 2013
    Inventors: Ravi Bhatia, Smita Bhatia, Stephen Forman, Jerald P. Radich, Liang Li, Min Li, Lue Ping Zhao
  • Patent number: 7671224
    Abstract: According to the present invention there is provided a compound in the form of a transition metal compound including a transition metal, a phosphorus containing ligand, and a cyclic organic ligand. The phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom which ligates with the transition metal, and which ligating phosphorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound. The cyclic organic ligand is a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which ligates with the transition metal by means of a double bound. The invention also relates to a method preparing such a compound and a metathesis reaction wherein such a compound is used as a catalyst.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: March 2, 2010
    Assignee: Umicore AG & Co. KG
    Inventors: Roland Winde, Ralf Wilhelm Karch, Andreas Rivas-Nass, Oliver Briel, Robert Paul Tooze, Grant Stephen Forman, Wolfgang Hubert Meyer
  • Patent number: 7446179
    Abstract: The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9+ malignancies and for abrogating any untoward B cell function. The chimeric receptor is a single chain scFvFc:? receptor where scFvFc designates the extracellular domain, scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ? represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain ? are linked by a transmembrane domain such as the transmembrane domain of CD4. In one aspect, the chimeric receptor comprises amino acids 23-634 of SEQ I DNO:2.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: November 4, 2008
    Assignee: City of Hope
    Inventors: Micahel C. Jensen, Stephen Forman, Andrew Raubitschek
  • Publication number: 20080221345
    Abstract: According to the present invention there is provided a compound in the form of a transition metal compound including a transition metal, a phosphorus containing ligand, and a cyclic organic ligand. The phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom which ligates with the transition metal, and which ligating phosphorus atom is an atom in the heterocyclic ring structure of the heterocyclic organic compound. The cyclic organic ligand is a cyclic organic compound with a ligating carbon atom in the cyclic ring structure of the cyclic organic compound which ligates with the transition metal by means of a double bound. The invention also relates to a method preparing such a compound and a metathesis reaction wherein such a compound is used as a catalyst.
    Type: Application
    Filed: July 12, 2006
    Publication date: September 11, 2008
    Inventors: Roland Winde, Ralf Wilhelm Karch, Andreas Rivas-Nass, Oliver Briel, Robert Paul Tooze, Grant Stephen Forman, Wolfgang Hubert Meyer
  • Patent number: 7276616
    Abstract: The use of a phosphorus containing Ligand as a Ligand for a metathesis catalyst in a catalysed metathesis reaction wherein the phosphorus containing Ligand is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound. The invention also relates to a metathesis catalyst such a phosphorus containing Ligand and to a metathesis reaction using the catalyst.
    Type: Grant
    Filed: July 4, 2003
    Date of Patent: October 2, 2007
    Assignee: Sasol Technology (UK) Limited
    Inventors: Catherine Lynn Dwyer, Ann Elizabeth Catherine McConnell, Grant Stephen Forman
  • Publication number: 20040126363
    Abstract: Genetically engineered, CD19-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CD19, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD19+ malignancies and for abrogating any untoward B cell function. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain scFvFc:&zgr; receptor where scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and &zgr; represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain &zgr; are linked by a transmembrane domain such as the transmembrane domain of CD4. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
    Type: Application
    Filed: May 7, 2003
    Publication date: July 1, 2004
    Inventors: Michael C. Jensen, Stephen Forman, Andrew Raubitschek